LONG-TERM ASPIRIN IN THE PREVENTION OF CARDIOVASCULAR DISORDERS - RECENT DEVELOPMENTS AND VARIATIONS ON A THEME

被引：11

作者：

CATELLALAWSON, F

FITZGERALD, GA

机构：

[1] Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania

[2] 909 Biomedical Research, University of Pennsylvania School of Medicine, Philadelphia, PA, 19104-6100, Building One

来源：

DRUG SAFETY | 1995年 / 13卷 / 02期

关键词：

D O I：

10.2165/00002018-199513020-00001

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Aspirin should be considered to have established efficacy as treatment for the long term prevention of cardiovascular events. However, no controlled studies of aspirin administration were extended beyond 5 years, and its use for a longer period is consequently empiric. Presently, its risk-benefit profile supports its indefinite use in high risk patients, but not in the healthy population. Alternative formulations of aspirin, drug combination strategies as well as new, more potent antithrombotic agents, such as orally bioavailable thrombin inhibitors and glycoprotein IIb/IIIa antagonists, are under investigation. These strategies will probably widen the indications for long term platelet inhibition. Results achieved with the intravenously administered monoclonal antibody abciximab, have demonstrated that the efficacy of IIb/IIIa antagonists is additive to that of aspirin.15 Oral IIb/III antagonists have already been shown to induce dose-dependent inhibition of platelet aggregation for an extended period of time53 and are currently in clinical development. Long term treatment with these compounds might be beneficial in indications which aspirin lacks efficacy, such as in the prevention of late thrombotic events and/or restenosis following coronary angioplasty. © 1995, Adis International Limited. All rights reserved.

引用

页码：69 / 75

页数：7

共 54 条

[41]

Kune G.A., Kune S., Watson L.F., Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study, Cancer Res, 48, pp. 399-404, (1988)

[42]

Thun M.J., Namboodiri M.M., Heath C.W., Aspirin use and reduced risk of fatal colon cancer, N Engl J Med, 325, (1991)

[43]

Rosenberg L., Palmer J.R., Zauber A.G., Et al., A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer, J Natl Cancer Inst, 83, (1991)

[44]

Waterhouse D., Aspirin, NSAIDs and risk reduction of colorectal cancer, Arch Intern Med, 154, (1994)

[45]

Winde G., Gumbinger H.G., Osswald H., Et al., The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis

[46]

clinical results of a dose-finding study on rectal sulindac administration, Int J Colorectal Dis, 8, (1993)

[47]

Spagnesi M.T., Tonelli F., Dolara P., Et al., Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment, Gastroenterology, 106, (1994)

[48]

Eberhart C.E., Coffey R.J., Radhika A., Et al., Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas, Gastroenterology, 107, (1994)

[49]

Mitchell J.A., Akarasereenont P., Thiemermann C., Et al., Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase, Proc Natl Acad Sci USA, 90, (1994)

[50]

Laneuville O., Breuer D.K., Dewitt D.L., Et al., Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs, J Pharmacol Exp Ther, 271, (1994)

← 1 2 3 4 5 6 →